Corey J. Langer, M.D.
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-138
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-138
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-5121
Fax: 215-615-5122
Lab: CP 215-806-6152
Fax: 215-615-5122
Lab: CP 215-806-6152
Education:
B.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Permanent linkB.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Description of Research Expertise
Maturing role of immunotherapy in advanced NSCLC.Role of targeted agents in oncogene-driven NSCLC
New strategies in SCLC
Unique combined modality strategies integrating radiation and systemic treatment in LA-NSCLC and limited stage SCLC
Underserved populations, including older patients and those with compromised performance status.
Novel therapeutic venues in thoracic and head and neck cancer
Description of Clinical Expertise
Thoracic Medical Oncology with focus on NSCLC, SCLC, and MesotheliomaSelected Publications
Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C.: Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy. Clin Lung Cancer 26(2): 158-163.e2, March 2025.Stalker M, Marmarelis M, Langer C, Cohen RB, Singh A, Aggarwal C, Sun L.: Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC. Clin Lung Cancer 26(2): 124-130.e1, March 2025.
Marmarelis ME, Scholes DG, McWilliams TL, Hwang WT, Kosteva J, Costello MR, Sun L, Singh AP, Lau-Min KS, Doucette A, Gabriel PE, Martella AO, Roy MA, Thompson JC, Cohen RB, Dougherty DW, Shulman LN, Langer CJ, Bekelman JE, Carpenter EL, Aggarwal C.: Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical Trial. JCO Oncol Pract 20(12), Dec 2024.
Meyer ML, Hirsch FR, Bunn PA, Ujhazy P, Fredrickson D, Berg CD, Carbone DP, Halmos B, Singh H, Borghaei H, Ferris A, Langer C, Dacic S, Mok TS, Peters S, Johnson BE.: Calls to action on lung cancer management and research. Oncologist 29(12): e1634-e1645, Dec 2024.
Barsouk A, Elghawy O, Heidlauf A, Yu C, Wang L, Yang D, Kurian M, Goel K, Rushkin L, Anran Huang A, Reed-Guy L, Bleiberg B, Sun L, Singh A, Cohen RB, Aggarwal C, Marmarelis M, Langer C.: Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib. Lung Cancer Aug 2024.
Thompson JC, Tilsed C, Davis C, Gupta A, Melidosian B, Sun C, Kallen ME, Timmers C, Langer CJ, Albelda SM.: Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line Patients. Cancers (Basel) 16: 2795, Aug 2024.
Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Carpenter EL, Langer CJ, Wherry EJ, Minn AJ.: Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384(6702): eadf1329, Jun 2024.
Corey J. Langer, Rachel Galot, Hans Prenen, David S. Hong, Iván Victoria, Ravi Salgia, Maxime Chenard-Poirier, Muhammad Furqan, Emily Chan, Jane Nolte-Hippenmeyer, Caihong Xia, and Bob T. Li: Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study. Journal of Clinical Oncology 42(16), June 2024.
Iocolano M, Yegya-Raman N, Friedes C, Wang X, Kegelman T, Lee SH, Duan L, Li B, Levin WP, Cengel KA, Konski A, Langer CJ, Cohen RB, Sun L, Aggarwal C, Doucette A, Xiao Y, Kevin Teo BK, O'Reilly S, Zou W, Bradley JD, Simone CB 2nd, Feigenberg SJ.: Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era. Cancer 130(11): 2031-2041, Jun 2024.
Yegya-Raman N, Berman AT, Ciunci CA, Friedes C, Berlin E, Iocolano M, Wang X, Lai C, Levin WP, Cengel KA, O'Reilly SE, Cohen RB, Aggarwal C, Marmarelis ME, Singh AP, Sun L, Bradley JD, Plastaras JP, Simone CB 2nd, Langer CJ, Feigenberg SJ.: Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 119(1): 56-65, May 2024.